BACKGROUND: Fragile X-associated tremor/ataxia syndrome (FXTAS), caused by premutation expansions (55-200 CGG repeats) of the FMR1 gene, shares clinical features with other movement disorders, particularly in the domains of gait ataxia, intention tremor and parkinsonism. However, the prevalence of FXTAS within other diagnostic categories is not well defined. METHODS: A meta-analysis was conducted of all published (n = 14) genetic screens for expanded FMR1 alleles to assess the prevalence and CGG-repeat size bias of FMR1 premutation alleles in those populations. RESULTS: In men with late-onset cerebellar ataxia, the prevalence of premutation alleles (1.5%; 16/1049) was 13 times greater than expected based on its prevalence in the general population (2%; 16/818 for age of onset >50 years; odds ratio 12.4; 95% confidence interval 1.6 to 93.5). Meta-analysis of CGG-repeat data for screened patients with premutation alleles shows a shift to larger repeat size than in the general population (p<0.001). 86% (19/22) of premutation alleles were larger than 70 repeats in the patients screened, whereas only approximately 22% of premutation alleles are larger than 70 repeats in the general population. CONCLUSIONS: Expanded FMR1 alleles contribute to cases of late-onset sporadic cerebellar ataxia, suggesting that FMR1 genetic testing should be carried out in such cases. The biased distribution of FMR1 allele sizes has substantial implications for genetic counselling of carriers with smaller alleles who are at a low risk of developing FXTAS, and suggests that the estimated prevalence of FXTAS among men >50 years of age in the general population may be two to threefold lower than the initial figure of 1 in 3000.
BACKGROUND:Fragile X-associated tremor/ataxia syndrome (FXTAS), caused by premutation expansions (55-200 CGG repeats) of the FMR1 gene, shares clinical features with other movement disorders, particularly in the domains of gait ataxia, intention tremor and parkinsonism. However, the prevalence of FXTAS within other diagnostic categories is not well defined. METHODS: A meta-analysis was conducted of all published (n = 14) genetic screens for expanded FMR1 alleles to assess the prevalence and CGG-repeat size bias of FMR1 premutation alleles in those populations. RESULTS: In men with late-onset cerebellar ataxia, the prevalence of premutation alleles (1.5%; 16/1049) was 13 times greater than expected based on its prevalence in the general population (2%; 16/818 for age of onset >50 years; odds ratio 12.4; 95% confidence interval 1.6 to 93.5). Meta-analysis of CGG-repeat data for screened patients with premutation alleles shows a shift to larger repeat size than in the general population (p<0.001). 86% (19/22) of premutation alleles were larger than 70 repeats in the patients screened, whereas only approximately 22% of premutation alleles are larger than 70 repeats in the general population. CONCLUSIONS: Expanded FMR1 alleles contribute to cases of late-onset sporadic cerebellar ataxia, suggesting that FMR1 genetic testing should be carried out in such cases. The biased distribution of FMR1 allele sizes has substantial implications for genetic counselling of carriers with smaller alleles who are at a low risk of developing FXTAS, and suggests that the estimated prevalence of FXTAS among men >50 years of age in the general population may be two to threefold lower than the initial figure of 1 in 3000.
Authors: R J Hagerman; M Leehey; W Heinrichs; F Tassone; R Wilson; J Hills; J Grigsby; B Gage; P J Hagerman Journal: Neurology Date: 2001-07-10 Impact factor: 9.910
Authors: H Toledano-Alhadef; L Basel-Vanagaite; N Magal; B Davidov; S Ehrlich; V Drasinover; E Taub; G J Halpern; N Ginott; M Shohat Journal: Am J Hum Genet Date: 2001-07-06 Impact factor: 11.025
Authors: W T Brown; G E Houck; A Jeziorowska; F N Levinson; X Ding; C Dobkin; N Zhong; J Henderson; S S Brooks; E C Jenkins Journal: JAMA Date: 1993-10-06 Impact factor: 56.272
Authors: R J Hagerman; B R Leavitt; F Farzin; S Jacquemont; C M Greco; J A Brunberg; F Tassone; D Hessl; S W Harris; L Zhang; T Jardini; L W Gane; J Ferranti; L Ruiz; M A Leehey; J Grigsby; P J Hagerman Journal: Am J Hum Genet Date: 2004-04-02 Impact factor: 11.025
Authors: Cesa Scaglione; Andrea Ginestroni; Alessandra Vella; Maria Teresa Dotti; Riccardo Della Nave; Giovanni Rizzo; Maria Teresa De Cristofaro; Nicola De Stefano; Silvia Piacentini; Paolo Martinelli; Mario Mascalchi Journal: J Neurol Date: 2007-12-19 Impact factor: 4.849
Authors: James A Bourgeois; Sarah M Coffey; Susan M Rivera; David Hessl; Louise W Gane; Flora Tassone; Claudia Greco; Brenda Finucane; Lawrence Nelson; Elizabeth Berry-Kravis; Jim Grigsby; Paul J Hagerman; Randi J Hagerman Journal: J Clin Psychiatry Date: 2009-05-05 Impact factor: 4.384
Authors: Igor Albizua; Benjamin L Rambo-Martin; Emily G Allen; Weiya He; Ashima S Amin; Stephanie L Sherman Journal: Am J Med Genet A Date: 2017-09-21 Impact factor: 2.802
Authors: Bruna P Brylawski; Paul D Chastain; Stephanie M Cohen; Marila Cordeiro-Stone; David G Kaufman Journal: Exp Mol Pathol Date: 2006-12-28 Impact factor: 3.362
Authors: James A Bourgeois; Andreea L Seritan; E Melina Casillas; David Hessl; Andrea Schneider; Ying Yang; Inderjeet Kaur; Jennifer B Cogswell; Danh V Nguyen; Randi J Hagerman Journal: J Clin Psychiatry Date: 2010-08-24 Impact factor: 4.384
Authors: Allyn McConkie-Rosell; Liane Abrams; Brenda Finucane; Amy Cronister; Louise W Gane; Sarah M Coffey; Stephanie Sherman; Lawrence M Nelson; Elizabeth Berry-Kravis; David Hessl; Sufen Chiu; Natalie Street; Ajay Vatave; Randi J Hagerman Journal: J Genet Couns Date: 2007-05-12 Impact factor: 2.537
Authors: E G Allen; J Juncos; R Letz; M Rusin; D Hamilton; G Novak; L Shubeck; S W Tinker; S L Sherman Journal: J Med Genet Date: 2008-01-30 Impact factor: 6.318